AC
VVOS icon

Armistice Capital’s Vivos Therapeutics VVOS Stock Holding History

Armistice Capital’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.32M Buy
+1,115,859
New +$1.79M 0.02% 162
2024
Q2 		– Sell
-103,582
Closed -$500K – 386
2024
Q1 		$500K Buy
103,582
+46,582
+82% +$278K 0.01% 201
2023
Q4 		$709K Buy
+57,000
New +$489K 0.01% 187

Other funds holding VVOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital's VVOS Position: Q1 2026 in Review

Armistice Capital opened a new position in Vivos Therapeutics (VVOS) in Q1 2026: 1,115,859 shares worth $1.32M. The stake represents 0.02% of the portfolio and ranks #162 among its holdings. This is a return to the name: Armistice Capital previously reported a position in VVOS as recently as Q1 2024.

Armistice Capital first reported a position in VVOS in Q4 2023 and has held it in 3 quarters since. 24 funds tracked by Wall St. Rank hold VVOS as of Q1 2026.

  • Armistice Capital held 1,115,859 shares of Vivos Therapeutics worth $1.32M as of Q1 2026.
  • Vivos Therapeutics was a new Armistice Capital position in Q1 2026.
  • Vivos Therapeutics made up 0.02% of Armistice Capital's portfolio in Q1 2026, its #162 holding.
  • Armistice Capital first reported a position in Vivos Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 24 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.